Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04108013
Other study ID # XWh-NSCLC-NEO-IIT-SHR1210
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date October 8, 2019
Est. completion date July 31, 2021

Study information

Verified date September 2019
Source Xuanwu Hospital, Beijing
Contact Shuyang Yao
Phone 15810401496
Email yaoshuyang@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a randomized, controlled, open-label, prospective, single-center phase II clinical study. Target population is patients with stage II and IIIA resectable non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to evaluate the major pathologic response of SHR-1210 + carboplatin + paclitaxel-albumin in subjects with resectable non-small cell lung cancer. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.


Description:

In this study, eligible subject will be randomized into study arm or control arm to accept study treatment. Subjects who randomized into control will have the opportunity to receive the treatment of carboplatin + paclitaxel-albumin therapy after confirmed disease progression. Treatment cycles of chemotherapy will be 2.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 38
Est. completion date July 31, 2021
Est. primary completion date July 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Male or female 18-70 years of age.

2. ECOG performance status of 0 or 1.

3. Life expectancy = 12 weeks.

4. Subjects are diagnosed with histologically or cytologically confirmed NSCLC.

5. Subjects are diagnosed with resectable stage II, stage IIIA non-small cell lung cancer.

6. Subjects enrolled must have measurable lesion(s) according to the RECIST 1.1 standard (the CT scan length of the tumor lesion > 10 mm, the short diameter of CT scan of the lymph node lesions > 15 mm).

7. Subjects haven't received radiotherapy, chemotherapy, surgery and targeted therapy before admission.

8. Subjects must have adequate pulmonary function for expected pneumonectomy.

9. The main organ's function is normal and it should meet the following criteria:

(1)Blood routine examination should be complied with (No blood transfusion, no use of hematopoietic factors and no use of drugs for correction within 14 days):

a.ANC = 1.5×109/L; b.HB = 90 g/L; c.PLT = 100×109/L;

(2)Biochemical tests must meet the following criteria:

1. TBIL = 1.5ULN;

2. ALT?AST= 2.5 ULN (If abnormal liver function is caused by liver metastasis, ALT?AST< 5ULN;

3. sCr=1.5ULN,endogenous creatinine clearance rate=50ml/min(Cockcroft-Gault formula);

(3)Blood coagulation must meet the following criteria: INR=1.5 and APTT=1.5 ULN;

10.Women of childbearing age must undergo a serological pregnancy test within 3 days before the first dose with negative results and willing to use a medically approved and effective contraceptive method (e.g. intrauterine device, contraceptive pill or condom) during the study and within three months after the last dose. For male subjects whose partners are women of childbearing age, they should be sterilized surgically or agree to use effective contraceptive methods during the study and within three months after the last dose.

11.Subjects should be voluntarily participate in clinical studies and informed consent should be signed.

Exclusion Criteria:

1. Subjects have symptomatic central nervous system metastasis.

2. Subjects have a history of any active autoimmune disease or autoimmune disease including but not limited to the following: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism which can be included after hormone replacement therapy; Subjects with childhood asthma have been completely alleviated and without any intervention or vitiligo in adulthood can be included. Subjects who need medical intervention with bronchodilators can not be included.

3. Subjects with congenital or acquired immunodeficiency such as HIV infection, active hepatitis B (HBV DNA = 500 IU/ml), hepatitis C (hepatitis C antibody is positive and HCV-RNA is higher than the lower detection limit of the analysis method) or co-infection with hepatitis B and hepatitis C.

4. Subjects used immunosuppressive drugs excluding nasal spray and inhaled corticosteroids or systemic steroids at physiological doses(prednisolone=10 mg/day or other corticosteroids of the same pharmacophysiological dose) within 14 days before the first dose.

5. Subjects were vaccinated with live attenuated vaccine within 4 weeks before the first dose or during the study period.

6. Subjects has taken last systemic cytotoxic or radiotherapy treatment in the past 4 weeks or subjects are currently using other antineoplastic drugs.

7. Subjects suffered from other malignant tumors in the past three years.

8. There is evidence that subjects have pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-induced pneumonia and severe impairment of lung function.

9. Subjects have uncontrollable hypertension (systolic pressure = 140 mmHg or diastolic pressure = 90 mmHg), despite patients have taken the best drug treatment;

10. Subjects with grade II or above myocardial ischemia or myocardial infarction and poorly controlled arrhythmias (QTc interval > 450 ms for males and QTc interval < 470 ms for females). Subjects with grade III-IV cardiac insufficiency or with left ventricular ejection fraction (LVEF) less than 50% had myocardial infarction within 6 months before admission according to NYHA criteria. Subjects with grade II or above heart failure, uncontrolled angina, uncontrolled severe ventricular arrhythmias, clinically pericardial disease, acute ischemia or abnormal active conduction system.

11. The subjects developed severe infection within 4 weeks before the first dose (such as: intravenous antibiotics, antifungal or antiviral drugs), or fever of unknown reason (>38.5 °C) before the first dose or during the first screening period.

12. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation is known.

13. Pregnant or lactating women; Fertile subjects who are unwilling or unable to take effective contraceptive measures

14. It is known that subjects have allergic reaction, hypersensitivity reaction or intolerance to SHR-1210, paclitaxel-albumin or its excipients.

15. Investigators believe that there is any situation that could damage the subjects or cause the subjects to fail to meet or perform the research requirements.

Study Design


Intervention

Drug:
SHR-1210
In the experimental group, 200mg SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
Carboplatin and Paclitaxel-albumin
In the control group, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Xuanwu Hospital, Beijing

Outcome

Type Measure Description Time frame Safety issue
Primary Major pathologic response It is defined as residual tumors less than 10% after neoadjuvant chemotherapy. 3.5 months
Secondary Objective Response Rate It is defined as the proportion of patients whose tumors shrink to a predetermined size and maintain a minimum time limit. It includes the cases of CR and PR. 6.5 months
Secondary Pathological complete response No histologic evidence of malignancy or only the ingredients of carcinoma in situ was found in primary tumors. 3.5 months
See also
  Status Clinical Trial Phase
Terminated NCT03087448 - Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Phase 1
Recruiting NCT05042375 - A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Phase 3
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Terminated NCT05414123 - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Recruiting NCT05009836 - Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03219970 - Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
Recruiting NCT05949619 - A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors Phase 1/Phase 2
Recruiting NCT04054531 - Study of KN046 With Chemotherapy in First Line Advanced NSCLC Phase 2
Withdrawn NCT03519958 - Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Terminated NCT02580708 - Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer Phase 1/Phase 2
Completed NCT01871805 - A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Recruiting NCT05919641 - LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
Completed NCT03656705 - CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma Phase 1